<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjeev Sethi, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1217072877"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury on kidney biopsy with characteristic light microscopic changes, including hypercellularity and thickening of the glomerular basement membrane (GBM). MPGN is a histologic lesion and <strong>not</strong> a specific disease entity. As such, the discovery of the lesion of MPGN in a kidney biopsy is the start of an exploratory process leading to a diagnosis, not an end in itself.</p><p>This topic will review the pathology, pathogenesis, classification, clinical features, and diagnosis of MPGN. The treatments of the different types of MPGN, including recurrent MPGN following kidney transplantation, are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3058.html" rel="external">"Membranoproliferative glomerulonephritis: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7343.html" rel="external">"Membranoproliferative glomerulonephritis: Recurrence of idiopathic disease after transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H1"><span class="h1">PATHOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>MPGN, also known as mesangiocapillary glomerulonephritis, is a pattern of glomerular injury on light microscopy that is characterized by mesangial hypercellularity, endocapillary proliferation, and double-contour formation along the glomerular capillary walls  (<a class="graphic graphic_picture graphicRef67999 graphicRef78967" href="/z/d/graphic/67999.html" rel="external">picture 1A-B</a>). The term "MPGN" is derived from the two characteristic histologic changes:</p><p class="bulletIndent1"><span class="glyph">●</span>Thickened glomerular basement membrane (GBM) due to deposition of immune complexes and/or complement factors, interposition of the mesangial cell and other cellular elements between the GBM and the endothelial cell, and new basement membrane formation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased mesangial and endocapillary cellularity, often leading to a lobular appearance of the glomerular tuft. The increase in cellularity results from both proliferation of mesangial cells and influx of circulating monocytes.</p><p></p><p>Two primary mechanisms have been described in the pathogenesis of MPGN:</p><p class="bulletIndent1"><span class="glyph">●</span>Deposition of immune complexes or monoclonal immunoglobulins leading to activation of complement (immune complex/monoclonal immunoglobulin mediated). The immune complexes can be composed of environmental or autologous antigens, and some instances represent aggregation of monoclonal proteins, typically of the immunoglobulin family. The term "immune complex-mediated MPGN" is best applied in the infectious setting since a specific antigen is not documented in cases of MPGN associated with autoimmunity or a monoclonal gammopathy. (See <a class="local">'Immune complex/monoclonal immunoglobulin-mediated MPGN'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysregulation and persistent activation of the alternative complement pathway (complement mediated). (See <a class="local">'Complement-mediated MPGN'</a> below.)</p><p></p><p class="headingAnchor" id="H981933439"><span class="h1">CLASSIFICATION BASED UPON IMMUNOFLUORESCENCE MICROSCOPY</span><span class="headingEndMark"> — </span>MPGN has traditionally been classified as MPGN types I, II, and III based upon electron microscopic findings. However, advances in the understanding of processes involved in the pathogenesis of MPGN suggest that the electron microscopy (EM)-based classification can result in overlap among the types  (<a class="graphic graphic_algorithm graphicRef86556" href="/z/d/graphic/86556.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>]. (See <a class="local">'Classification based upon electron microscopy'</a> below.)</p><p>By contrast, a classification that is based upon the pathogenetic process helps to direct the clinical evaluation and provide a rationale for disease-specific treatments. In this system, MPGN is classified as being mediated by immune complexes or monoclonal immunoglobulins, complement dysregulation that leads to persistent activation of the alternative complement pathway, or, rarely, mechanisms not involving immunoglobulin or complement deposition, such as endothelial injury [<a href="#rid2">2</a>]. These disorders can be distinguished by immunofluorescence microscopy [<a href="#rid3">3,4</a>].</p><p>Immune complex/monoclonal immunoglobulin-mediated MPGN is characterized by the deposition of immunoglobulins and complement components, while complement-mediated MPGN is characterized by glomerular deposits of complement components in the absence of significant immunoglobulin deposition.</p><p class="headingAnchor" id="H455985606"><span class="h2">Immune complex/monoclonal immunoglobulin-mediated MPGN</span><span class="headingEndMark"> — </span>Immune complex-mediated MPGN results from chronic antigenemia and/or circulating immune complexes and can be seen in chronic infections and autoimmune diseases [<a href="#rid5">5,6</a>]. MPGN with immunoglobulin and complement deposits may also be observed in the setting of monoclonal gammopathies [<a href="#rid7">7-16</a>]. An underlying cause can be found in the great majority of cases [<a href="#rid3">3,4,17</a>], but despite a thorough evaluation, a small minority remain "idiopathic."</p><p>Immunofluorescence microscopy may suggest the underlying etiology of immune complex/monoclonal immunoglobulin-mediated MPGN:</p><p class="bulletIndent1"><span class="glyph">●</span>MPGN resulting from hepatitis C virus (HCV) infection typically shows granular deposition of immunoglobulin M (IgM), C3, and <strong>both</strong> kappa and lambda light chains. Immunoglobulin G (IgG) may or may not be present, and C1q is typically negative [<a href="#rid18">18</a>]. This pattern may also be seen with MPGN induced by other viral infections [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MPGN resulting from monoclonal gammopathy is characterized by deposition of monotypic immunoglobulin with kappa or lambda light chain restriction <strong>but not both</strong>. MPGN associated with either heavy or light chain deposition alone has also been described [<a href="#rid12">12,19</a>]. (See <a class="local">'Monoclonal gammopathies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MPGN resulting from autoimmune diseases is typically characterized by the "full house" pattern of immunoglobulin deposition, including IgG, IgM, immunoglobulin A (IgA), C1q, C3, C4, and kappa and lambda light chains [<a href="#rid20">20</a>].</p><p></p><p>EM in immunoglobulin-positive MPGN typically demonstrates subendothelial and mesangial deposits  (<a class="graphic graphic_picture graphicRef64411" href="/z/d/graphic/64411.html" rel="external">picture 2</a>). Subepithelial deposits can also be seen with autoimmune diseases. As an example, patients with diffuse proliferative lupus nephritis can also have lupus membranous glomerulopathy with subepithelial deposits  (<a class="graphic graphic_picture graphicRef69348" href="/z/d/graphic/69348.html" rel="external">picture 3</a>) [<a href="#rid18">18</a>]. However, EM alone does not differentiate between immune complex/monoclonal immunoglobulin-mediated and complement-mediated MPGN.</p><p>EM may suggest certain underlying diseases. As examples, tubuloreticular structures in endothelial cells in MPGN are suggestive of lupus nephritis  (<a class="graphic graphic_picture graphicRef79072" href="/z/d/graphic/79072.html" rel="external">picture 4</a>), and a fingerprint pattern associated with cryoprecipitates is seen in mixed cryoglobulinemia  (<a class="graphic graphic_picture graphicRef81450" href="/z/d/graphic/81450.html" rel="external">picture 5</a>) or rarely in lupus nephritis associated with cryoglobulinemia [<a href="#rid21">21</a>]. Intramembranous, linear, highly electron-dense deposits, with sausage-shaped deposits, are suggestive of dense deposit disease (DDD).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'Characteristic histopathologic findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis", section on 'Kidney involvement'</a>.)</p><p></p><p class="headingAnchor" id="H261825925"><span class="h3">Infections</span><span class="headingEndMark"> — </span>Immune complex-mediated MPGN is most commonly secondary to hepatitis C and B viral infections [<a href="#rid11">11,18,22-24</a>]. The incidence of HCV-associated MPGN varies with location. As examples, HCV appears to be a common cause of MPGN in Japan [<a href="#rid9">9</a>] but is an uncommon cause in France and South Africa [<a href="#rid25">25,26</a>]. HCV-induced MPGN is typically associated with mixed (type II) cryoglobulinemia.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection", section on 'Membranoproliferative glomerulonephritis without cryoglobulins'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3119.html" rel="external">"Kidney disease associated with hepatitis B virus infection", section on 'Membranoproliferative glomerulonephritis (MPGN)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis", section on 'Kidney involvement'</a>.)</p><p></p><p>In addition to HCV, chronic bacterial (eg, endocarditis, shunt nephritis, abscesses), fungal, and, particularly in the developing world, parasitic infections (eg, schistosomiasis, echinococcosis) can cause MPGN [<a href="#rid9">9,10,27-29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3054.html" rel="external">"Kidney disease in the setting of infective endocarditis or an infected ventriculoatrial shunt", section on 'Clinical features and kidney biopsy findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3057.html" rel="external">"Schistosomiasis and glomerular disease", section on 'Clinicopathologic manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H455985652"><span class="h3">Autoimmune disorders</span><span class="headingEndMark"> — </span>Immune complex-mediated MPGN is observed in patients with systemic lupus erythematosus (particularly in the chronic phase of lupus nephritis) and, less often, Sjögren's disease or rheumatoid arthritis [<a href="#rid15">15,16,30,31</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'Diffuse LN (class IV)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">"Kidney disease in primary Sjögren's disease", section on 'Nephritic syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H455985660"><span class="h3">Monoclonal gammopathies</span><span class="headingEndMark"> — </span>Monoclonal gammopathies are an important cause of MPGN and can be associated on immunofluorescence microscopy with either monoclonal immunoglobulin deposition, as discussed in this section [<a href="#rid14">14,32-39</a>], or isolated complement deposition in DDD and C3 glomerulonephritis (C3GN), as discussed below. (See <a class="local">'Complement-mediated MPGN'</a> below and <a class="local">'C3 dense deposit disease'</a> below.)</p><p>In a retrospective review of kidney biopsies performed at the Mayo Clinic, 28 of 68 patients (41 percent) who had a diagnosis of MPGN and were not infected with either hepatitis B or C virus had a monoclonal gammopathy, as determined by serum and/or urine electrophoresis [<a href="#rid14">14</a>]. A diagnosis of monoclonal gammopathy of undetermined significance (MGUS) was made in 16 patients; the 12 remaining patients had lymphoma or multiple myeloma. Most cases of MPGN and monoclonal immunoglobulin deposits (ie, proliferative glomerulonephritis with monoclonal immunoglobulin deposits [PGNMID]) are not associated with a symptomatic hematological disease but occur in the setting of a small, otherwise asymptomatic plasma cell or B cell clone. This situation in commonly referred to as monoclonal gammopathy of renal significance (MGRS) [<a href="#rid40">40</a>].</p><p>The clinical features and prognosis of PGNMID were described in a study of 37 patients who had monoclonal IgG deposits [<a href="#rid37">37</a>]. Nephrotic syndrome, kidney function impairment, and hematuria were present in 49, 68, and 77 percent, respectively. Of 32 patients who were followed for over two years, 22 percent progressed to end-stage kidney disease (ESKD), 38 percent had complete or partial recovery, and 38 percent had persistent kidney dysfunction. Only one patient had multiple myeloma.</p><p>For unclear reasons, most patients with PGNMID do not have a detectable circulating monoclonal gammopathy by serum and urine monoclonal protein testing and do not have detectable plasma cell or B cell clones on bone marrow aspirate and biopsy. There is a greater likelihood of finding a plasma cell clone by bone marrow biopsy if the monoclonal IgG is an IgG1 subtype or if the PGNMID is a light chain only variant [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance", section on 'Establishing the diagnosis'</a>.)</p><p>Cases of MPGN in patients with chronic lymphocytic leukemia have also been described, usually in association with mixed cryoglobulinemia or noncryoprecipitating monoclonal IgG or IgM [<a href="#rid39">39,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Other organ involvement'</a>.)</p><p>Patients with MPGN associated with monoclonal immunoglobulin deposits (PGNMID) have a very high rate of recurrent disease (approximately 70 percent) after kidney transplantation [<a href="#rid42">42,43</a>]. Recurrence typically occurs early posttransplant and is characterized by an aggressive course and high risk of graft failure [<a href="#rid42">42,43</a>]. Biopsy of the allograft often shows a mesangial proliferative pattern of injury that subsequently progresses to an MPGN pattern. Glomerular deposits are most often composed of IgG3 kappa, although other immunoglobulin isotypes and/or light chains have also been identified in the deposits; the prognostic implications of these immunoglobulin variations are unclear [<a href="#rid42">42</a>]. In two-thirds of cases (mainly IgG3 subtype), a monoclonal immunoglobulin cannot be detected in the serum or urine, and in these cases, bone marrow biopsy shows no evidence of a plasma cell disorder. In the other one-third of the patients, a monoclonal protein can be identified in the serum or urine, but most patients have an MGRS rather than multiple myeloma. (See  <a class="medical medical_review" href="/z/d/html/7343.html" rel="external">"Membranoproliferative glomerulonephritis: Recurrence of idiopathic disease after transplantation"</a>.)</p><p class="headingAnchor" id="H4155923547"><span class="h4">MPGN with masked deposits</span><span class="headingEndMark"> — </span>In rare cases, patients with MPGN associated with monoclonal gammopathy may present with isolated C3 deposits with no staining of immunoglobulins by standard immunofluorescence techniques [<a href="#rid44">44</a>]. Immunofluorescence on formalin-fixed, paraffin-embedded tissue after pronase digestion may reveal the presence of "masked" monoclonal immunoglobulin deposits. Positive staining for C4d, a byproduct of the classic and lectin complement pathways, can also be helpful in detecting "masked" immune deposits [<a href="#rid45">45,46</a>]. The immunoglobulin detected within glomerular deposits typically matches the monoclonal protein identified by serum or urine immunofixation in these patients. Failure to identify these "masked" monoclonal immunoglobulins can result in missing the diagnosis of monoclonal gammopathy-associated MPGN and incorrectly diagnosing these patients as having only C3GN. It is important that these cases are not misdiagnosed as C3 glomerulopathy, as most are associated with a low-grade lymphoma or plasma cell dyscrasia. (See  <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance", section on 'When to suspect MGRS'</a>.)</p><p class="headingAnchor" id="H274990906"><span class="h3">Rare causes</span><span class="headingEndMark"> — </span>Rare causes of MPGN include non-Hodgkin lymphoma [<a href="#rid47">47</a>], renal cell carcinoma [<a href="#rid48">48</a>], splenorenal shunt surgery for portal hypertension [<a href="#rid49">49</a>], melanoma [<a href="#rid50">50</a>], and alpha-1-antitrypsin deficiency [<a href="#rid51">51</a>]. Idiopathic MPGN is a diagnosis of exclusion [<a href="#rid52">52</a>] and is seldom encountered if the diagnostic evaluation is thorough. (See  <a class="medical medical_review" href="/z/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency", section on 'Glomerulonephritis'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Complement-mediated MPGN</span><span class="headingEndMark"> — </span>Complement-mediated MPGN is less common than immune complex/monoclonal immunoglobulin-mediated MPGN and results from dysregulation and persistent activation of the alternative complement pathway [<a href="#rid3">3,4,29,30</a>]. This form of MPGN is due to the deposition of complement products along the capillary walls and in the mesangium. Complement-mediated MPGN can be subdivided into C3 glomerulopathy and C4 glomerulopathy based upon the complement product identified within glomerular deposits. In C3 glomerulopathy, immunofluorescence microscopy of kidney sections demonstrates predominantly bright staining for C3, with minimal or no immunoglobulin staining, in the mesangium and along the capillary walls  (<a class="graphic graphic_picture graphicRef76040" href="/z/d/graphic/76040.html" rel="external">picture 6</a>) [<a href="#rid53">53</a>]. C4 glomerulopathy is characterized by bright staining for C4d, a degradation product of C4, with minimal or no C3 or immunoglobulin staining  (<a class="graphic graphic_picture graphicRef107059" href="/z/d/graphic/107059.html" rel="external">picture 7</a>).</p><p>Complement-mediated MPGN may be further classified based upon ultrastructural features observed on EM as DDD or C3 (or C4) glomerulonephritis. Some genetic mutations that have been associated with these disorders are also associated with atypical hemolytic uremic syndrome. (See  <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p>Hypocomplementemia is a characteristic finding in most patients with MPGN. However, a normal C3 concentration does not exclude complement-mediated MPGN, and it is not unusual to find a normal C3 concentration in the chronic phases of the disease, as in adults with DDD [<a href="#rid54">54</a>] or patients with C3GN [<a href="#rid55">55</a>]. Low C3 levels are also common in postinfectious glomerulonephritis and cannot be used to distinguish these two entities. However, anti-factor B antibodies have been reported to occur more frequently in children with acute postinfectious glomerulonephritis than in children with hypocomplementemic C3 glomerulopathy (91 versus 14 percent) [<a href="#rid56">56</a>]. (See <a class="local">'Clinical features'</a> below.)</p><p class="headingAnchor" id="H3915261863"><span class="h3">C3 glomerulopathy</span></p><p class="headingAnchor" id="H119004535"><span class="h4">C3 dense deposit disease</span><span class="headingEndMark"> — </span>C3 DDD (also called MPGN type II) is a rare form of MPGN that affects both children and young adults. It has also been associated with monoclonal gammopathies in older adults [<a href="#rid57">57</a>]. In the majority of patients, antibodies called C3 nephritic factors (C3NeFs) that stabilize C3 convertase are present in circulation. (See  <a class="medical medical_review" href="/z/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis"</a>.) </p><p>On light microscopy, patterns of injury other than MPGN can also be seen, including mesangial proliferative, diffuse proliferative, crescentic glomerulonephritis, and a sclerosing glomerulopathy. Immunofluorescence microscopy demonstrates C3 deposits, and EM (required to establish the diagnosis) shows the characteristic sausage-shaped, wavy, densely osmophilic deposits along the glomerular basement membranes (GBM) and mesangium (from which the disease receives its name)  (<a class="graphic graphic_picture graphicRef73319" href="/z/d/graphic/73319.html" rel="external">picture 8</a>). C3 DDD may be associated with lipodystrophy and presence of drusen on funduscopic examination. Rarely C3 DDD can be a consequence of a monoclonal gammopathy that interferes with the interaction of complement factor H and C3b causing persistent activation of the alternate complement pathway. (See  <a class="medical medical_review" href="/z/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H455985668"><span class="h4">C3 glomerulonephritis</span><span class="headingEndMark"> — </span>C3GN (also called glomerulonephritis with isolated C3 deposits) is, like C3 DDD, caused by excessive activation of the alternative complement cascade due (in most patients) to mutations in or antibodies to complement regulating proteins [<a href="#rid3">3,55,58-62</a>]. C3GN has also been reported in association with inherited disease due to mutations in the <em>CFHR5 </em>gene (CFHR5 nephropathy) and a mutation producing a <em>CFHR1-CFHR3</em> hybrid gene as well as with monoclonal gammopathies [<a href="#rid63">63,64</a>]. In one study of 95 patients with C3GN, among those 50 years and older, more than 60 percent had a circulating monoclonal protein [<a href="#rid65">65</a>]. This is in contrast to younger patients who are more likely to have genetic variants and/or autoantibodies to complement regulating proteins and do not have circulating monoclonal proteins. (See  <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance"</a> and <a class="local">'CFHR5 nephropathy'</a> below.)</p><p>Light microscopy often shows an MPGN pattern of injury, although other forms of glomerulonephritis may be seen, including mesangial proliferative, diffuse proliferative, crescentic glomerulonephritis, and a sclerosing glomerulopathy [<a href="#rid58">58,59,66-68</a>]. C3GN with severe crescentic glomerulonephritis is a rare subtype that more commonly affects children and young adults [<a href="#rid69">69</a>].</p><p>Immunofluorescence microscopy shows extensive C3 deposition along the capillary walls and mesangium  (<a class="graphic graphic_picture graphicRef76040" href="/z/d/graphic/76040.html" rel="external">picture 6</a>) with <strong>no</strong> significant immunoglobulin deposition [<a href="#rid3">3,58,59,70</a>]. EM demonstrates deposits that are similar to those seen with immune complex/monoclonal immunoglobulin-mediated MPGN but does not show the typical sausage-shaped intramembranous and mesangial deposits observed in DDD  (<a class="graphic graphic_picture graphicRef50927" href="/z/d/graphic/50927.html" rel="external">picture 9</a>).</p><p>Patients with C3GN typically present with proteinuria, which can be associated with nephrotic syndrome, hematuria, and variable degrees of hypertension and azotemia. C3 levels are low in less than 50 percent of cases, C4 levels are normal, and some patients have a C3 convertase-stabilizing autoantibody called C3 nephritic factor (or C3NeF), which is also seen in DDD [<a href="#rid58">58-60</a>]. A normal C3 does not exclude C3GN [<a href="#rid55">55,71</a>]. There may be progression to ESKD, and C3GN can recur after kidney transplantation.</p><p>Some patients develop hematuria after an upper respiratory infection (URI). In a report of nine patients who presented with hematuria following a nonstreptococcal URI and had glomerulonephritis on kidney biopsy, six had mesangial C3 deposits, and four had hypocomplementemia [<a href="#rid72">72</a>]. These findings suggest that the patients may have had a form of C3GN that had not been described at the time of publication. In addition, hematuria after a URI is well described in CFHR5 nephropathy, as described in the next section. The presence of drusen on funduscopic examination has also been reported in patients with C3GN [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H37578836"><span class="h5">CFHR5 nephropathy</span><span class="headingEndMark"> — </span>A familial form of C3GN has been described in patients of Cypriot origin due to a mutation in the gene for complement factor H-related protein 5 (<em>CFHR5</em>) [<a href="#rid74">74,75</a>]. In a cohort of 84 Cypriots with unexplained kidney disease, four (5 percent) had CFHR5 nephropathy, as detected by mutation analysis [<a href="#rid74">74</a>].</p><p>CFHR5 nephropathy has the following genetic features [<a href="#rid76">76</a>]. Inheritance is autosomal dominant with more than 90 percent penetrance. The mutation involves a genomic duplication in the <em>CFHR5</em> gene that results in an elongated version of the CFHR5 protein. The mutation is present in approximately 1 in 6500 Cypriots and is associated with an extended haplotype flanking the mutation, pointing toward a common ancestor.</p><p>The clinical manifestations include hematuria in approximately 90 percent, accompanied by proteinuria in 38 percent [<a href="#rid75">75</a>]. Episodes of macroscopic (gross) hematuria can occur within one to two days of a URI and can be recurrent [<a href="#rid74">74</a>]. The serum C3 concentrations at presentation have been poorly characterized among patients with CFHR5 nephropathy. Among <em>CHFR5</em> mutation carriers over age 50 years, men are much more likely than women to develop chronic kidney disease (80 versus 21 percent) and ESKD (78 versus 4 percent) [<a href="#rid75">75</a>]. The development of proteinuria (greater than 1 to 1.5 g/day) is a major predictor of a progressive disease [<a href="#rid75">75</a>]. Recurrent nephropathy can occur in transplanted kidneys [<a href="#rid77">77</a>]. There is no treatment of proven efficacy.</p><p class="headingAnchor" id="H1217075066"><span class="h5">Distinction from postinfectious glomerulonephritis</span><span class="headingEndMark"> — </span>Some patients with MPGN have subepithelial and subendothelial deposits on EM (ie, MPGN type III as described below) and are complement positive but immunoglobulin negative by immunofluorescence microscopy. Some of these cases have been attributed to resolving postinfectious glomerulonephritis because of the presence of subepithelial deposits on EM, even in the absence of a history of recent infection. Atypical, persistent, or resolving postinfectious glomerulonephritis are terms that have been used to describe such cases. In such cases, bright C3 staining and lack of significant immunoglobulin staining raise the possibility of C3GN. Consistent with this hypothesis, abnormalities in the alternative complement pathway have been found in many of these patients [<a href="#rid55">55,78-81</a>] and likely represent cases of undiagnosed C3GN [<a href="#rid81">81</a>]. By contrast, postinfectious glomerulonephritis is associated with both bright C3 staining and IgG deposition  (<a class="graphic graphic_picture graphicRef56846" href="/z/d/graphic/56846.html" rel="external">picture 10</a>).</p><p>Findings on EM may also help to distinguish C3GN from postinfectious glomerulonephritis. C3GN is usually associated with abundant large mesangial, subendothelial, and occasionally subepithelial or intramembranous deposits that have a fuzzy amorphous lobular quality  (<a class="graphic graphic_picture graphicRef50927" href="/z/d/graphic/50927.html" rel="external">picture 9</a>). This is in contrast to the well-demarcated subepithelial humps seen in postinfectious glomerulonephritis  (<a class="graphic graphic_picture graphicRef76739" href="/z/d/graphic/76739.html" rel="external">picture 11</a>). (See  <a class="medical medical_review" href="/z/d/html/6118.html" rel="external">"Poststreptococcal glomerulonephritis", section on 'Pathology'</a>.)</p><p>Low C3 levels are common in both postinfectious glomerulonephritis and C3GN and cannot be used to distinguish these two entities. However, anti-factor B antibodies have been reported to occur more frequently in children with acute postinfectious glomerulonephritis than in children with hypocomplementemic C3 glomerulopathy (91 versus 14 percent) [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H2818828479"><span class="h3">C4 glomerulopathy</span><span class="headingEndMark"> — </span>C4 glomerulopathy, which includes C4 DDD and C4GN, is a rare disorder characterized by the glomerular deposition of C4 in the absence of C3, C1q, and immunoglobulin [<a href="#rid82">82,83</a>]. Unlike patients with C3 glomerulopathy, those with C4 glomerulopathy do not have congenital or acquired defects in the alternative pathway of complement; however, they may have an overactive lectin pathway of complement. A more detailed discussion of C4 glomerulopathy is presented separately. (See  <a class="medical medical_review" href="/z/d/html/103208.html" rel="external">"C4 glomerulopathy"</a>.)</p><p class="headingAnchor" id="H455985677"><span class="h2">MPGN without immunoglobulin or complement deposition</span><span class="headingEndMark"> — </span>A histologic pattern that may resemble MPGN on light microscopy can be seen in the healing phase of thrombotic microangiopathies (eg, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome), antiphospholipid antibody syndrome, nephropathy associated with bone marrow transplantation, chronic kidney allograft nephropathy, radiation nephritis, and malignant hypertension.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney", section on 'Kidney manifestations of antiphospholipid syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Thrombotic microangiopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7359.html" rel="external">"Kidney transplantation in adults: Chronic allograft nephropathy", section on 'Characteristic findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">"Diagnosis of immune TTP", section on 'Neurologic and other organ involvement'</a>.)</p><p></p><p>The common underlying cause of the MPGN pattern in such patients is endothelial injury followed by reparative changes. Immunofluorescence microscopy does not show significant immunoglobulin or complement deposition in the glomeruli, and EM does not show electron-dense deposits along the capillary walls.</p><p class="headingAnchor" id="H559999613"><span class="h1">CLASSIFICATION BASED UPON ELECTRON MICROSCOPY</span><span class="headingEndMark"> — </span>MPGN was initially classified into types I, II, and III based upon electron microscopy (EM). However, this classification has important limitations, and we prefer the classification based upon immunofluorescence microscopy. The classification based upon EM is presented here solely for historical reasons. (See <a class="local">'Limitations of this classification'</a> below.)</p><p class="headingAnchor" id="H92986245"><span class="h2">MPGN type I</span><span class="headingEndMark"> — </span>MPGN type I is characterized by discrete immune deposits in the mesangium and subendothelial space, similar to that seen in lupus nephritis, that are thought to reflect the deposition of circulating immune complexes  (<a class="graphic graphic_picture graphicRef64411" href="/z/d/graphic/64411.html" rel="external">picture 2</a>).</p><p class="headingAnchor" id="H92986252"><span class="h2">MPGN type II</span><span class="headingEndMark"> — </span>MPGN type II (dense deposit disease [DDD]) is characterized by continuous, dense ribbon-like deposits along the basement membranes of the glomeruli, tubules, and Bowman's capsule  (<a class="graphic graphic_picture graphicRef73319" href="/z/d/graphic/73319.html" rel="external">picture 8</a>) [<a href="#rid84">84-86</a>]. (See  <a class="medical medical_review" href="/z/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis"</a>.)</p><p class="headingAnchor" id="H92986267"><span class="h2">MPGN type III</span><span class="headingEndMark"> — </span>MPGN type III is similar to MPGN type I except that subepithelial deposits are noted as well as subendothelial deposits  (<a class="graphic graphic_picture graphicRef77236" href="/z/d/graphic/77236.html" rel="external">picture 12</a>). Based upon the EM findings, MPGN type III is further classified into two principal variants, the Strife and Anders variant and the Burkholder variant, which have different patterns of electron-dense deposits and disorganization of the glomerular basement membrane (GBM) [<a href="#rid87">87-90</a>].</p><p>Many cases of MPGN type III that are immunoglobulin negative but complement positive by immunofluorescence microscopy have been attributed to resolving postinfectious glomerulonephritis because of the presence of subepithelial humps on EM, despite the absence of a history of recent infection. In such cases, bright C3 staining and lack of significant immunoglobulin staining raise the possibility of C3 glomerulonephritis (C3GN). Consistent with this hypothesis, subsequent evaluation demonstrated abnormalities of the alternative complement pathway in many of these patients. (See <a class="local">'C3 glomerulonephritis'</a> above.)</p><p class="headingAnchor" id="H92986221"><span class="h2">Limitations of this classification</span><span class="headingEndMark"> — </span>Understanding the limitations of the EM classification requires a brief review of complement activation pathways. There are two main pathways: the classic pathway, which is activated when IgG or IgM antibodies bind to antigens, and the alternative pathway, which does not require the presence of antibodies and can be autoactivated by spontaneous cleavage of C3 to C3b, leading to the formation of C3 convertase  (<a class="graphic graphic_figure graphicRef59641" href="/z/d/graphic/59641.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system", section on 'Pathways and activating conditions'</a>.)</p><p>The EM-based classification can result in overlap between types I and III. Both types have been considered to be immune complex-mediated glomerulonephritides because of the presence of immune-type electron-dense deposits in the mesangium and subendothelial space. However, the following observations suggest that some cases with EM features of MPGN type I or MPGN type III are mediated by complement, not immune, complexes:</p><p class="bulletIndent1"><span class="glyph">●</span>Some cases of MPGN type I have been associated with strong C3 staining without immunoglobulin staining by immunofluorescence microscopy, consistent with a process mediated by complement alternative pathway rather than immune complexes [<a href="#rid91">91</a>]. (See <a class="local">'Complement-mediated MPGN'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of cases of MPGN type III show strong C3 staining without immunoglobulin staining by immunofluorescence microscopy, again consistent with a process mediated by complement alternative pathway rather than immune complexes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Markedly depressed serum C3 levels with normal or only mildly decreased serum C4 and C1q levels have been observed in patients with MPGN type I, suggesting possible activation of the alternative rather than the classical complement pathway activated by immune complexes [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A C3 convertase-stabilizing antibody (called C3 nephritic factor [C3NeF]) is found in approximately 80 percent of patients with DDD and results in activation of the alternative complement pathway that characterizes DDD. However, different C3NeFs have been identified in some patients with MPGN types I and III [<a href="#rid92">92,93</a>]. (See  <a class="medical medical_review" href="/z/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis", section on 'Pathogenesis'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is an inherited form of MPGN type III that is linked to chromosome 1q32, the locus for the complement receptor family [<a href="#rid94">94,95</a>]. These genes code for a highly homologous group of proteins that regulate C3 convertase activity. Abnormalities in any of these proteins may cause excess circulating C3b, mimicking the action of C3NeF [<a href="#rid94">94</a>]. (See  <a class="medical medical_review" href="/z/d/html/3967.html" rel="external">"Regulators and receptors of the complement system"</a>.)</p><p></p><p class="headingAnchor" id="H40631997"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The clinical presentation of MPGN is similar to that in other types of glomerulonephritis. In patients with active disease, the urine sediment reveals hematuria, typically with dysmorphic red cells  (<a class="graphic graphic_picture graphicRef130438" href="/z/d/graphic/130438.html" rel="external">picture 13</a> and <a class="graphic graphic_picture graphicRef62064" href="/z/d/graphic/62064.html" rel="external">picture 14</a>) and occasionally with red cell casts  (<a class="graphic graphic_picture graphicRef55778" href="/z/d/graphic/55778.html" rel="external">picture 15</a>); there is a variable degree of proteinuria; and the serum creatinine may be normal or elevated. Occasional patients with indolent disease present late in the course at a time when active inflammation has subsided. Such patients may have a bland urine sediment with a variable degree of proteinuria and elevation in serum creatinine. The diagnosis is made by kidney biopsy [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p>Hypocomplementemia is common in all types of MPGN [<a href="#rid18">18,54,85,87,96</a>]. In immune complex/monoclonal immunoglobulin-mediated MPGN, complement activation occurs via the classic pathway and is typically manifested by a normal or mildly decreased serum C3 concentration and a low serum C4 concentration. In complement-mediated MPGN, there are usually low serum C3 and normal C4 levels due to activation of the alternate pathway [<a href="#rid85">85</a>]. However, complement-mediated MPGN is not excluded by a normal serum C3 concentration, and it is not unusual to find a normal C3 concentration in adults with dense deposit disease (DDD) [<a href="#rid54">54</a>] or C3 glomerulonephritis (C3GN). (See <a class="local">'Complement-mediated MPGN'</a> above.)</p><p>Among patients who have the different forms of MPGN described above, there are generally no differences in clinical presentation with the possible exception of patients with DDD, which is a form of complement-mediated MPGN that is associated with drusen formation that may be seen on funduscopic examination and with partial lipodystrophy. (See  <a class="medical medical_review" href="/z/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H2813117214"><span class="h1">EVALUATION OF THE PATIENT WITH AN MPGN LESION</span><span class="headingEndMark"> — </span>As previously stated, MPGN is a histologic lesion and not a specific disease entity. The identification of an MPGN lesion in a kidney biopsy does not establish a specific diagnosis; rather, it should prompt the clinician to pursue a thorough evaluation to determine the underlying cause of the MPGN lesion. (See <a class="local">'Classification based upon immunofluorescence microscopy'</a> above.)</p><p class="headingAnchor" id="H2816207031"><span class="h2">Classification of the MPGN lesion</span><span class="headingEndMark"> — </span>The causes and evaluation of MPGN differ in immune complex/monoclonal immunoglobulin-mediated, complement-mediated disease, and MPGN without immunoglobulin and complement deposition. Thus, the initial step we take in evaluating the patient with an MPGN lesion is to classify the MPGN lesion based upon the immunofluorescence microscopy findings on kidney biopsy  (<a class="graphic graphic_algorithm graphicRef86556" href="/z/d/graphic/86556.html" rel="external">algorithm 1</a>) (see <a class="local">'Classification based upon immunofluorescence microscopy'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with positive staining for polyclonal immunoglobulins <strong>and </strong>complement by immunofluorescence microscopy most likely have immune complex-mediated MPGN. (See <a class="local">'Immune complex/monoclonal immunoglobulin-mediated MPGN'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MPGN with monoclonal immunoglobulin deposits most likely have an underlying clonal B cell or plasma cell disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with positive staining for C3 (or, rarely, C4d) <strong>and no or minimal</strong> staining for immunoglobulin by immunofluorescence microscopy  (<a class="graphic graphic_picture graphicRef76040" href="/z/d/graphic/76040.html" rel="external">picture 6</a>) most likely have complement-mediated MPGN. (See <a class="local">'Complement-mediated MPGN'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with no or minimal staining for immunoglobulin <strong>and</strong> complement most likely have MPGN as a result of endothelial injury followed by reparative changes. (See <a class="local">'MPGN without immunoglobulin or complement deposition'</a> above.)</p><p></p><p class="headingAnchor" id="H2299020475"><span class="h2">Subsequent evaluation based upon classification</span><span class="headingEndMark"> — </span>Subsequent evaluation for the cause of the MPGN lesion is based upon the classification of the MPGN lesion:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune complex/monoclonal immunoglobulin-mediated MPGN</strong> – In patients who have findings consistent with immune complex/monoclonal immunoglobulin-mediated MPGN, we evaluate for the following disorders:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infections</strong> – A variety of infections can lead to MPGN. Hepatitis B and hepatitis C virus (HCV) should be excluded by serology, while chronic bacterial infections should be excluded by culture, including blood cultures when clinically indicated. We do not test for fungi in the absence of a suggestive history (eg, fever of unknown origin, unexplained pulmonary infiltrates) or for parasitic infections (eg, malaria, schistosomiasis, leishmaniasis) unless the patient resides in or has visited an endemic site. Patients with a history of recent sore throat or skin infection should undergo serologic testing for recent streptococcal infection. Antibodies to factor B have been described as frequently occurring in patients with acute postinfectious glomerulonephritis in children [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/6867.html" rel="external">"Evaluation of acute pharyngitis in adults", section on 'Testing for GAS'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autoimmune diseases</strong> – Autoimmune diseases that have been associated with MPGN include systemic lupus erythematosus and rarely Sjögren's disease and systemic sclerosis [<a href="#rid15">15,30,31,97</a>]. Such patients almost always have manifestations of the underlying disease, and other than serologic testing for lupus, we would not evaluate for Sjögren's disease and systemic sclerosis in the absence of suggestive manifestations. The specific evaluation of these disorders is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'Evaluation and diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a> and  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monoclonal gammopathy</strong> – Monoclonal gammopathies should be excluded by serum protein electrophoresis and immunofixation, serum free light chains, and urine protein electrophoresis and immunofixation. Newer techniques for detecting plasma cell disorders based on mass spectrometry are emerging, which have improved clinical and analytical performance when compared with immunofixation [<a href="#rid98">98,99</a>]. </p><p></p><p class="bulletIndent2">Urine free light chains have no diagnostic utility and should not be performed. Bone marrow examination may be required to identify the clone (B cell or plasma cell) producing the pathogenic monoclonal immunoglobulin, in order to delivery appropriate chemotherapy. However, the yield of a bone marrow biopsy finding a clone in the absence of a circulating monoclonal protein is low. Most patients with MPGN and a monoclonal gammopathy have no identifiable disease; this disorder has been called MPGN associated with monoclonal gammopathy of renal significance (MGRS) [<a href="#rid100">100</a>]. In a report from the Mayo Clinic of 68 patients with MPGN who were not infected with HCV, 28 (41 percent) had a monoclonal gammopathy on serum and/or urine electrophoresis [<a href="#rid14">14</a>]. Most of these patients had no identifiable underlying disease and were considered to have monoclonal gammopathy of undetermined significance (MGUS). (See  <a class="medical medical_review" href="/z/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance"</a>.)</p><p></p><p class="bulletIndent2">However, occasional patients with a monoclonal gammopathy and MPGN have a serious and potentially treatable cause. These include multiple myeloma, low-grade B cell lymphoma, and chronic lymphocytic leukemia [<a href="#rid14">14,37,39,101</a>]. These disorders may be diagnosed at presentation or later after an initial diagnosis of MGUS [<a href="#rid101">101</a>]. As described below, treatment of these disorders can lead to improvement in the MPGN. (See  <a class="medical medical_review" href="/z/d/html/3058.html" rel="external">"Membranoproliferative glomerulonephritis: Treatment and prognosis", section on 'Patients with an underlying cause'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complement-mediated MPGN</strong> – In patients who have findings consistent with complement-mediated MPGN, we perform an evaluation for activation of the alternative pathway of complement [<a href="#rid102">102,103</a>]. We suggest measuring C3, C4, CH50 (which provides a measure of activation of the classic complement pathway), and AH50 (which provides a measure of activation of the alternative complement pathway). All patients with a complement-mediated MPGN should undergo genetic analysis for mutations and allele variants of complement factors and assays for autoantibodies to complement regulating proteins (eg, factors H and I), including testing for C3 nephritic factor (C3NeF) and, if available, serum levels of the membrane attack complex. Factor H and other measurements, including C3 activation and breakdown products, C3NeF, and mutation screening of a variety of complement related genes including factor H are available in select research laboratories  (<a class="graphic graphic_table graphicRef110840" href="/z/d/graphic/110840.html" rel="external">table 1</a>). A plasma cell disorder should also be excluded [<a href="#rid14">14,63,65,104</a>]. (See <a class="local">'Complement-mediated MPGN'</a> above and  <a class="medical medical_review" href="/z/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis", section on 'Establishing the diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have findings consistent with MPGN without immunoglobulin or complement deposition, we evaluate for causes of chronic thrombotic microangiopathy (eg, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome) as well as for antiphospholipid antibody syndrome. (See  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a> and  <a class="medical medical_review" href="/z/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H2137984988"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H80906099"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles </strong>– Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury on kidney biopsy with characteristic light microscopic changes, including hypercellularity and thickening of the glomerular basement membrane (GBM). MPGN is a histologic lesion and <strong>not</strong> a specific disease entity. As such, the discovery of the lesion of MPGN in a kidney biopsy is the start of an exploratory process leading to a diagnosis, not an end in itself. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification </strong>– MPGN has traditionally been classified as MPGN types I, II, and III based upon electron microscopic findings. However, electron microscopy (EM)-based classification can result in overlap among the types. As such, the EM classification for MPGN is primarily of historical interest, and its use should be discouraged. (See <a class="local">'Classification based upon electron microscopy'</a> above.)</p><p></p><p class="bulletIndent1">By contrast, a classification that is based upon the pathogenetic process helps to direct the clinical evaluation and provide a rationale for disease-specific treatments. In this system, MPGN is classified as being mediated by immune complexes or monoclonal immunoglobulins, complement dysregulation that leads to persistent activation of the alternative complement pathway, or, rarely, mechanisms not involving immunoglobulin or complement deposition, such as endothelial injury. These disorders can be distinguished by immunofluorescence microscopy. (See <a class="local">'Classification based upon immunofluorescence microscopy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– The clinical presentation of MPGN is similar to that in other types of glomerulonephritis. In patients with active disease, the urine sediment reveals hematuria, typically with dysmorphic red cells and occasionally with red cell casts; there is a variable degree of proteinuria; and the serum creatinine may be normal or elevated. Hypocomplementemia is common in all types of MPGN. Occasional patients with indolent disease present late in the course at a time when active inflammation has subsided. Such patients may have a bland urine sediment with a variable degree of proteinuria and elevation in serum creatinine. The diagnosis is made by kidney biopsy. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of the patient with an MPGN lesion </strong>– The identification of an MPGN lesion in a kidney biopsy does not establish a specific diagnosis; rather, it should prompt the clinician to pursue a thorough evaluation to determine the underlying cause of the MPGN lesion. The initial step we take in evaluating the patient with an MPGN lesion is to classify the MPGN lesion based upon the immunofluorescence microscopy findings on kidney biopsy  (<a class="graphic graphic_algorithm graphicRef86556" href="/z/d/graphic/86556.html" rel="external">algorithm 1</a>). (See <a class="local">'Classification of the MPGN lesion'</a> above.)</p><p></p><p class="bulletIndent1">Subsequent evaluation for the cause of the MPGN lesion is based upon the classification of the MPGN lesion (see <a class="local">'Subsequent evaluation based upon classification'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who have findings consistent with immune complex-mediated MPGN, we evaluate for infections (such as hepatitis B and C virus and chronic bacterial infections), autoimmune diseases (such as systemic lupus erythematosus). In patients with MPGN and monotypic immunoglobulin deposits, we evaluate for monoclonal gammopathy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who have findings consistent with complement-mediated MPGN, we perform an evaluation for activation of the alternative pathway of complement. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who have findings consistent with MPGN without immunoglobulin or complement deposition, we evaluate for causes of chronic thrombotic microangiopathy (eg, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome) as well as for antiphospholipid antibody syndrome. </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med 2012; 366:1119.</a></li><li><a class="nounderline abstract_t">Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 2012; 81:434.</a></li><li><a class="nounderline abstract_t">Sethi S, Fervenza FC, Zhang Y, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 6:1009.</a></li><li><a class="nounderline abstract_t">Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31:341.</a></li><li><a class="nounderline abstract_t">Nasr SH, Fogo AB. New developments in the diagnosis of fibrillary glomerulonephritis. Kidney Int 2019; 96:581.</a></li><li><a class="nounderline abstract_t">Nasr SH, Valeri AM, Cornell LD, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011; 6:775.</a></li><li><a class="nounderline abstract_t">Boseman P, Lewin M, Dillon J, Sethi S. Marfan syndrome, MPGN, and bacterial endocarditis. Am J Kidney Dis 2008; 51:697.</a></li><li><a class="nounderline abstract_t">Hulton SA, Risdon RA, Dillon MJ. Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5. Pediatr Nephrol 1992; 6:239.</a></li><li><a class="nounderline abstract_t">Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6:220.</a></li><li><a class="nounderline abstract_t">Yamabe H, Johnson RJ, Gretch DR, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995; 25:67.</a></li><li><a class="nounderline abstract_t">Alpers CE, Smith KD. Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens 2008; 17:243.</a></li><li><a class="nounderline abstract_t">Vella J, Carmody M, Campbell E, et al. Glomerulonephritis after ventriculo-atrial shunt. QJM 1995; 88:911.</a></li><li><a class="nounderline abstract_t">Adam FU, Torun D, Bolat F, et al. Acute renal failure due to mesangial proliferative glomerulonephritis in a pregnant woman with primary Sjögren's syndrome. Clin Rheumatol 2006; 25:75.</a></li><li><a class="nounderline abstract_t">Sethi S, Zand L, Leung N, et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010; 5:770.</a></li><li><a class="nounderline abstract_t">Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65:521.</a></li><li><a class="nounderline abstract_t">Zand L, Fervenza FC, Nasr SH, Sethi S. Membranoproliferative glomerulonephritis associated with autoimmune diseases. J Nephrol 2014; 27:165.</a></li><li><a class="nounderline abstract_t">Glassock RJ, Bargman JM, Palmer BF, et al. Nephrology Quiz and Questionnaire: 2009. Clin J Am Soc Nephrol 2010; 5:1141.</a></li><li><a class="nounderline abstract_t">Rennke HG. Secondary membranoproliferative glomerulonephritis. Kidney Int 1995; 47:643.</a></li><li><a class="nounderline abstract_t">Nasr SH, Larsen CP, Sirac C, et al. Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. Kidney Int 2020; 97:589.</a></li><li><a class="nounderline abstract_t">Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241.</a></li><li><a class="nounderline abstract_t">Su CF, Chen HH, Yeh JC, et al. Ultrastructural 'fingerprint' in cryoprecipitates and glomerular deposits: a clinicopathologic analysis of fingerprint deposits. Nephron 2002; 90:37.</a></li><li><a class="nounderline abstract_t">Doutrelepont JM, Adler M, Willems M, et al. Hepatitis C infection and membranoproliferative glomerulonephritis. Lancet 1993; 341:317.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.</a></li><li><a class="nounderline abstract_t">Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 2005; 14:396.</a></li><li><a class="nounderline abstract_t">Rostoker G, Deforges L, Ben Maadi A, et al. Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France. Nephron 1995; 69:97.</a></li><li><a class="nounderline abstract_t">Madala ND, Naicker S, Singh B, et al. The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection. Clin Nephrol 2003; 60:69.</a></li><li><a class="nounderline abstract_t">Martinelli R, Noblat AC, Brito E, Rocha H. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy. Kidney Int 1989; 35:1227.</a></li><li><a class="nounderline abstract_t">Rodrigues VL, Otoni A, Voieta I, et al. Glomerulonephritis in schistosomiasis mansoni: a time to reappraise. Rev Soc Bras Med Trop 2010; 43:638.</a></li><li><a class="nounderline abstract_t">Rincón B, Bernis C, Garcia A, Traver JA. Mesangiocapillary glomerulonephritis associated with hydatid disease. Nephrol Dial Transplant 1993; 8:783.</a></li><li><a class="nounderline abstract_t">Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) 2000; 79:241.</a></li><li><a class="nounderline abstract_t">Cortez MS, Sturgill BC, Bolton WK. Membranoproliferative glomerulonephritis with primary Sjögren's syndrome. Am J Kidney Dis 1995; 25:632.</a></li><li><a class="nounderline abstract_t">Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease--diagnosis and treatment. Clin J Am Soc Nephrol 2007; 2:858.</a></li><li><a class="nounderline abstract_t">Alpers CE, Tu WH, Hopper J Jr, Biava CG. Single light chain subclass (kappa chain) immunoglobulin deposition in glomerulonephritis. Hum Pathol 1985; 16:294.</a></li><li><a class="nounderline abstract_t">Chang A, Peutz-Kootstra CJ, Richardson CA, Alpers CE. Expanding the pathologic spectrum of light chain deposition disease: a rare variant with clinical follow-up of 7 years. Mod Pathol 2005; 18:998.</a></li><li><a class="nounderline abstract_t">Soares SM, Lager DJ, Leung N, et al. A proliferative glomerulonephritis secondary to a monoclonal IgA. Am J Kidney Dis 2006; 47:342.</a></li><li><a class="nounderline abstract_t">Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 2004; 65:85.</a></li><li><a class="nounderline abstract_t">Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009; 20:2055.</a></li><li><a class="nounderline abstract_t">Masai R, Wakui H, Komatsuda A, et al. Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol 2009; 72:46.</a></li><li><a class="nounderline abstract_t">Moulin B, Ronco PM, Mougenot B, et al. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 1992; 42:127.</a></li><li><a class="nounderline abstract_t">Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019; 15:45.</a></li><li><a class="nounderline abstract_t">Barbour SJ, Beaulieu MC, Zalunardo NY, Magil AB. Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. Nephrol Dial Transplant 2011; 26:2712.</a></li><li><a class="nounderline abstract_t">Nasr SH, Sethi S, Cornell LD, et al. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol 2011; 6:122.</a></li><li><a class="nounderline abstract_t">Lorenz EC, Sethi S, Leung N, et al. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int 2010; 77:721.</a></li><li><a class="nounderline abstract_t">Larsen CP, Messias NC, Walker PD, et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015; 88:867.</a></li><li><a class="nounderline abstract_t">Sethi S, Hernandez LH, Alexander MP, Fervenza FC. C4d as a marker for masked immune deposits. Kidney Int 2016; 90:223.</a></li><li><a class="nounderline abstract_t">Sethi S, Nasr SH, De Vriese AS, Fervenza FC. C4d as a Diagnostic Tool in Proliferative GN. J Am Soc Nephrol 2015; 26:2852.</a></li><li><a class="nounderline abstract_t">Rault R, Holley JL, Banner BF, el-Shahawy M. Glomerulonephritis and non-Hodgkin's lymphoma: a report of two cases and review of the literature. Am J Kidney Dis 1992; 20:84.</a></li><li><a class="nounderline abstract_t">Ahmed M, Solangi K, Abbi R, Adler S. Nephrotic syndrome, renal failure, and renal malignancy: an unusual tumor-associated glomerulonephritis. J Am Soc Nephrol 1997; 8:848.</a></li><li><a class="nounderline abstract_t">Dash SC, Bhuyan UN, Dinda AK, et al. Increased incidence of glomerulonephritis following spleno-renal shunt surgery in non-cirrhotic portal fibrosis. Kidney Int 1997; 52:482.</a></li><li><a class="nounderline abstract_t">Olson JL, Philips TM, Lewis MG, Solez K. Malignant melanoma with renal dense deposits containing tumor antigens. Clin Nephrol 1979; 12:74.</a></li><li><a class="nounderline abstract_t">Sethi S, Theis JD, Vrana JA, et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol 2013; 8:915.</a></li><li><a class="nounderline abstract_t">Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 2012; 27:4288.</a></li><li><a class="nounderline abstract_t">Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84:1079.</a></li><li><a class="nounderline abstract_t">Nasr SH, Valeri AM, Appel GB, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4:22.</a></li><li><a class="nounderline abstract_t">Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82:465.</a></li><li><a class="nounderline abstract_t">Chauvet S, Berthaud R, Devriese M, et al. Anti-Factor B Antibodies and Acute Postinfectious GN in Children. J Am Soc Nephrol 2020; 31:829.</a></li><li><a class="nounderline abstract_t">Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56:977.</a></li><li><a class="nounderline abstract_t">Servais A, Frémeaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44:193.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Frémeaux-Bacchi V, Noël LH, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494.</a></li><li><a class="nounderline abstract_t">Habbig S, Mihatsch MJ, Heinen S, et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75:1230.</a></li><li><a class="nounderline abstract_t">Fakhouri F, de Jorge EG, Brune F, et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010; 78:279.</a></li><li><a class="nounderline abstract_t">Zand L, Kattah A, Fervenza FC, et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 2013; 62:506.</a></li><li><a class="nounderline abstract_t">Bridoux F, Desport E, Frémeaux-Bacchi V, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 2011; 6:2165.</a></li><li><a class="nounderline abstract_t">Malik TH, Lavin PJ, Goicoechea de Jorge E, et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012; 23:1155.</a></li><li><a class="nounderline abstract_t">Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 2018; 94:178.</a></li><li><a class="nounderline abstract_t">Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens 2007; 16:204.</a></li><li><a class="nounderline abstract_t">Servais A, Noël LH, Dragon-Durey MA, et al. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol 2011; 42:1305.</a></li><li><a class="nounderline abstract_t">Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011; 20:271.</a></li><li><a class="nounderline abstract_t">Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulonephritis with a severe crescentic phenotype. Pediatr Nephrol 2017; 32:1625.</a></li><li><a class="nounderline abstract_t">D'Agati VD, Bomback AS. C3 glomerulopathy: what's in a name? Kidney Int 2012; 82:379.</a></li><li><a class="nounderline abstract_t">Servais A, Noël LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82:454.</a></li><li><a class="nounderline abstract_t">Smith MC, Cooke JH, Zimmerman DM, et al. Asymptomatic glomerulonephritis after nonstreptococcal upper respiratory infections. Ann Intern Med 1979; 91:697.</a></li><li><a class="nounderline abstract_t">Dalvin LA, Fervenza FC, Sethi S, Pulido JS. Manifestations of Complement-Mediated and Immune Complex-Mediated Membranoproliferative Glomerulonephritis: A Comparative Consecutive Series. Ophthalmology 2016; 123:1588.</a></li><li><a class="nounderline abstract_t">Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376:794.</a></li><li><a class="nounderline abstract_t">Athanasiou Y, Voskarides K, Gale DP, et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6:1436.</a></li><li><a class="nounderline abstract_t">Gale DP, Pickering MC. Regulating complement in the kidney: insights from CFHR5 nephropathy. Dis Model Mech 2011; 4:721.</a></li><li><a class="nounderline abstract_t">Vernon KA, Gale DP, de Jorge EG, et al. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. Am J Transplant 2011; 11:152.</a></li><li><a class="nounderline abstract_t">Frémeaux-Bacchi V, Weiss L, Demouchy C, et al. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant 1994; 9:1747.</a></li><li><a class="nounderline abstract_t">Halbwachs L, Leveillé M, Lesavre P, et al. Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme. J Clin Invest 1980; 65:1249.</a></li><li><a class="nounderline abstract_t">Glovsky MM, Ward PA, Johnson KJ. Complement determinations in human disease. Ann Allergy Asthma Immunol 2004; 93:513.</a></li><li><a class="nounderline abstract_t">Sethi S, Fervenza FC, Zhang Y, et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 2013; 83:293.</a></li><li><a class="nounderline abstract_t">Sethi S, Sullivan A, Smith RJ. C4 dense-deposit disease. N Engl J Med 2014; 370:784.</a></li><li><a class="nounderline abstract_t">Sethi S, Quint PS, O'Seaghdha CM, et al. C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition. Am J Kidney Dis 2016; 67:949.</a></li><li><a class="nounderline abstract_t">Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16:1392.</a></li><li><a class="nounderline abstract_t">Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18:2447.</a></li><li><a class="nounderline abstract_t">Sethi S, Gamez JD, Vrana JA, et al. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75:952.</a></li><li><a class="nounderline abstract_t">Strife CF, Jackson EC, McAdams AJ. Type III membranoproliferative glomerulonephritis: long-term clinical and morphologic evaluation. Clin Nephrol 1984; 21:323.</a></li><li><a class="nounderline abstract_t">Strife CF, McEnery PT, McAdams AJ, West CD. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 1977; 7:65.</a></li><li><a class="nounderline abstract_t">Burkholder PM, Marchand A, Krueger RP. Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study. Lab Invest 1970; 23:459.</a></li><li><a class="nounderline abstract_t">Anders D. [Membranoproliferative glomerulonephritis]. Dtsch Med Wochenschr 1977; 102:1295.</a></li><li><a class="nounderline abstract_t">Levy M, Gubler MC, Sich M, et al. Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN). Clin Immunol Immunopathol 1978; 10:477.</a></li><li><a class="nounderline abstract_t">Clardy CW, Forristal J, Strife CF, West CD. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clin Immunol Immunopathol 1989; 50:333.</a></li><li><a class="nounderline abstract_t">Strife CF, Prada AL, Clardy CW, et al. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. J Pediatr 1990; 116:S98.</a></li><li><a class="nounderline abstract_t">Neary JJ, Conlon PJ, Croke D, et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol 2002; 13:2052.</a></li><li><a class="nounderline abstract_t">Neary J, Dorman A, Campbell E, et al. Familial membranoproliferative glomerulonephritis type III. Am J Kidney Dis 2002; 40:E1.</a></li><li><a class="nounderline abstract_t">Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983; 74:175.</a></li><li><a class="nounderline abstract_t">Waldherr R, Seelig HP, Klare B, Abigt J. Membranoproliferative glomerulonephritis in systemic sclerosis of childhood. Virchows Arch A Pathol Anat Histol 1978; 379:169.</a></li><li><a class="nounderline abstract_t">Dasari S, Kohlhagen MC, Dispenzieri A, et al. Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. Mayo Clin Proc 2022; 97:294.</a></li><li><a class="nounderline abstract_t">Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J 2021; 11:24.</a></li><li><a class="nounderline abstract_t">Bridoux F, Leung N, Hutchison CA, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015; 87:698.</a></li><li><a class="nounderline abstract_t">Guiard E, Karras A, Plaisier E, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 2011; 6:1609.</a></li><li><a class="nounderline abstract_t">De Vriese AS, Sethi S, Van Praet J, et al. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol 2015; 26:2917.</a></li><li><a class="nounderline abstract_t">Angioi A, Fervenza FC, Sethi S, et al. Diagnosis of complement alternative pathway disorders. Kidney Int 2016; 89:278.</a></li><li><a class="nounderline abstract_t">Ravindran A, Fervenza FC, Smith RJH, et al. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clin Proc 2018; 93:991.</a></li></ol></div><div id="topicVersionRevision">Topic 3055 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22435371" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Membranoproliferative glomerulonephritis--a new look at an old entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157657" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415311" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21839367" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31227146" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : New developments in the diagnosis of fibrillary glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21441134" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fibrillary glomerulonephritis: a report of 66 cases from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18371546" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Marfan syndrome, MPGN, and bacterial endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616831" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579088" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7810536" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18408474" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cryoglobulinemia and renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8593552" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Glomerulonephritis after ventriculo-atrial shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917985" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute renal failure due to mesangial proliferative glomerulonephritis in a pregnant woman with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185597" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717922" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The classification of glomerulonephritis in systemic lupus erythematosus revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500888" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Membranoproliferative glomerulonephritis associated with autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498249" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nephrology Quiz and Questionnaire: 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7723253" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Secondary membranoproliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001067" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747370" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The classification of glomerulonephritis in systemic lupus erythematosus revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11744803" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ultrastructural 'fingerprint' in cryoprecipitates and glomerular deposits: a clinicopathologic analysis of fingerprint deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8093965" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hepatitis C infection and membranoproliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7678440" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15931011" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pathogenic mechanisms in membranoproliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7534382" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940606" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2504987" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21181014" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Glomerulonephritis in schistosomiasis mansoni: a time to reappraise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8414165" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mesangiocapillary glomerulonephritis associated with hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10941353" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702063" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Membranoproliferative glomerulonephritis with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699503" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A case of atypical light chain deposition disease--diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3918930" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Single light chain subclass (kappa chain) immunoglobulin deposition in glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696120" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Expanding the pathologic spectrum of light chain deposition disease: a rare variant with clinical follow-up of 7 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16431264" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A proliferative glomerulonephritis secondary to a monoclonal IgA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675039" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470674" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Proliferative glomerulonephritis with monoclonal IgG deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19640387" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1635342" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30510265" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21633102" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876681" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20130531" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Recurrent membranoproliferative glomerulonephritis after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26154922" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27312449" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : C4d as a marker for masked immune deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25991041" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : C4d as a Diagnostic Tool in Proliferative GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1621685" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Glomerulonephritis and non-Hodgkin's lymphoma: a report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176859" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Nephrotic syndrome, renal failure, and renal malignancy: an unusual tumor-associated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264006" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Increased incidence of glomerulonephritis following spleno-renal shunt surgery in non-cirrhotic portal fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/393445" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Malignant melanoma with renal dense deposits containing tumor antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23411427" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22798508" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Idiopathic membranoproliferative glomerulonephritis: does it exist?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24172683" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : C3 glomerulopathy: consensus report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971369" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22673887" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32034108" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Anti-Factor B Antibodies and Acute Postinfectious GN in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20832153" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Dense deposit disease associated with monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018561" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20606628" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : C3 glomerulopathy: a new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633337" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : C3 deposition glomerulopathy due to a functional factor H defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20445496" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23623956" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : C3 glomerulonephritis associated with monoclonal gammopathy: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784830" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626820" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A hybrid CFHR3-1 gene causes familial C3 glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29729982" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420663" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dense deposit disease: new insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21396679" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Heterogeneous pattern of renal disease associated with homozygous factor H deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422921" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Complement and glomerular disease: new insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28593446" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : C3 glomerulonephritis with a severe crescentic phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22846813" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : C3 glomerulopathy: what's in a name?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22456601" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/227300" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Asymptomatic glomerulonephritis after nonstreptococcal upper respiratory infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26996341" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Manifestations of Complement-Mediated and Immune Complex-Mediated Membranoproliferative Glomerulonephritis: A Comparative Consecutive Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800271" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21566112" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22065842" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Regulating complement in the kidney: insights from CFHR5 nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114651" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7708258" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6902727" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15609759" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Complement determinations in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235567" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552345" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : C4 dense-deposit disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26896898" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800116" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17675665" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : New approaches to the treatment of dense deposit disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19177158" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6331934" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Type III membranoproliferative glomerulonephritis: long-term clinical and morphologic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/844227" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4921796" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/902593" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : [Membranoproliferative glomerulonephritis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/357058" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2917424" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2329415" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12138136" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12087587" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Familial membranoproliferative glomerulonephritis type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6337487" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/150697" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Membranoproliferative glomerulonephritis in systemic sclerosis of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34887112" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33563895" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25607108" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Diagnosis of monoclonal gammopathy of renal significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700823" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26185203" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26806831" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Diagnosis of complement alternative pathway disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30077216" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
